Its adjusted ebitda increased by 26% and its operating profit by 27%, reaching US$89.4 million and US$84.2 million, respectively, which the company says indicates strong operating performance.
UltraGreen.ai, a global market leader in the sale of indocyanine green (ICG) used in surgeries, reported FY2025 ended Dec 31, 2025 earnings of US$75.6 million ($96.9 million) for its first financial report card since its IPO last December, an increase of 35% over the preceding FY2024.
Revenue in the same period was up 24% to US$142.4 million, driven by a 14% increase in the volume of vials shipped and a 17% increase in average selling price. The company maintained its gross margin at 85%.
